Table 3. The cox proportional hazard regression analyses for overall survival in training and validation cohort.
| Variables | Training Cohort | Validation Cohort | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. | Univariable Analysis | Multivariable Analysis | No. | Univariable Analysis | Multivariable Analysis | |||||
| HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | |||
| Gender | ||||||||||
| Female | 13 | Reference | 16 | Reference | ||||||
| Male | 103 | 1.076 (0.598–1.932) | 0.539 | NA | 50 | 1.072 (0.681–1.684) | 0.207 | NA | ||
| Age (years) | ||||||||||
| ≤ 60 | 93 | Reference | 56 | Reference | ||||||
| > 60 | 23 | 1.285 (0.826–2.332) | 0.276 | NA | 10 | 1.238 (0.645–2.662) | 0.311 | NA | ||
| AFP(ng/mL) | ||||||||||
| ≤ 20 | 56 | Reference | 23 | Reference | ||||||
| > 20 | 60 | 1.127 (0.906–1.854) | 0.437 | NA | 43 | 1.104 (0.804–1.623) | 0.412 | NA | ||
| HBsAg | ||||||||||
| Negative | 29 | Reference | 18 | Reference | ||||||
| Positive | 87 | 1.174 (0.768–2.159) | 0.362 | NA | 48 | 1.658 (0.785–2.631) | 0.396 | NA | ||
| Liver cirrhosis | ||||||||||
| Absence | 31 | Reference | 29 | Reference | ||||||
| Presence | 85 | 1.332 (0.680–2.609) | 0.218 | NA | 37 | 1.206 (0.660–2.153) | 0.254 | NA | ||
| Child-Pugh classification | ||||||||||
| A | 102 | Reference | 59 | Reference | ||||||
| B | 14 | 1.439 (0.724–2.860) | 0.147 | NA | 7 | 1.134 (0.941–2.034) | 0.126 | NA | ||
| Tumor number | ||||||||||
| Solitary | 56 | Reference | Reference | 32 | Reference | Reference | ||||
| Multiple | 60 | 3.972 (1.433–6.587) | < 0.001 | 1.795 (1.187–2.753) | 0.047 | 34 | 3.054 (1.625–5.154) | 0.001 | 1.837 (1.351–2.985) | 0.021 |
| Tumor size | ||||||||||
| ≤ 5 cm | 39 | Reference | 17 | Reference | ||||||
| > 5 cm | 77 | 1.306 (0.969–1.846) | 0.158 | NA | 49 | 1.402 (0.743–2.851) | 0.343 | NA | ||
| Capsular formation | ||||||||||
| Presence | 52 | Reference | Reference | 36 | Reference | Reference | ||||
| Absence | 64 | 3.834 (1.972–7.624) | 0.014 | 2.036 (1.288–4.732) | 0.029 | 30 | 1.506 (1.041–2.198) | 0.040 | 1.145 (0.837–1.517) | 0.109 |
| Microvascular invasion | ||||||||||
| Absence | 68 | Reference | Reference | 41 | Reference | Reference | ||||
| Presence | 48 | 3.459 (1.645–4.252) | 0.002 | 2.678 (1.437–3.107) | 0.012 | 25 | 2.755 (1.952–4.245) | 0.009 | 2.028 (1.556–3.551) | 0.013 |
| Edmondson-Steiner grade | ||||||||||
| Low grade (I and II) | 36 | Reference | Reference | 30 | Reference | |||||
| High grade (III and IV) | 80 | 1.381 (1.012–2.783) | 0.037 | 1.064 (0.804–1.801) | 0.094 | 36 | 1.542 (0.955–2.275) | 0.302 | NA | |
| TNM Stage | ||||||||||
| I | 51 | Reference | Reference | 27 | Reference | Reference | ||||
| II–III | 65 | 2.728 (1.579–5.668) | 0.017 | 1.625 (1.256–3.254) | 0.039 | 39 | 2.661 (1.108–6.356) | 0.012 | 1.814 (1.581–3.861) | 0.047 |
| BCLC Stage | ||||||||||
| 0–A | 49 | Reference | Reference | 21 | Reference | Reference | ||||
| B–C | 67 | 3.137 (1.791–6.138) | 0.001 | 2.506 (1.231–5.097) | 0.026 | 45 | 2.796 (1.985–4.643) | 0.015 | 1.735 (1.352–3.192) | 0.041 |
| Tumor JARID2 expression | ||||||||||
| Low | 47 | Reference | Reference | 28 | Reference | Reference | ||||
| High | 69 | 2.956 (1.351–5.014) | 0.005 | 1.873 (1.108–3.845) | 0.041 | 38 | 2.963 (1.704–5.162) | 0.018 | 2.241 (1.568–3.811) | 0.031 |
Abbreviations: AFP, alpha-fetoprotein; TNM, tumor node metastasis; BCLC, Barcelona Clinic Liver Cancer; Tumor JARID2 expression, JARID2 expression in HCC tissues.